Romiplostim

5 trials 2 recruiting BHaematology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

4 Sponsors

9 Countries

Phase III

Phase II

Phase III: 3 Phase II: 2

Indications tested

Immune thrombocytopenia 2 Breast cancer 1 Non-small cell lung cancer 1 Gastrointestinal cancer metastatic 1 Thrombocytopenia 1 Colorectal adenocarcinoma 1 Ovarian cancer 1

Sponsors using this IMP

Amgen Inc. 2 Centre Hospitalier Universitaire De Nantes 1 Fakultni Nemocnice Hradec Kralove 1 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla 1

All trials

5 total

Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded co… Pending

2024-517710-15-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM) Recruiting

2023-505788-35-00 Phase II 1 country Fakultni Nemocnice Hradec Kralove
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Phase III 5 countries Amgen Inc.
Clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune … Ended

2024-514147-28-00 Phase III 2 countries Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended

2023-507148-35-00 Phase III 8 countries Amgen Inc.

Showing 1–5 of 5 trials

← All drugs A–Z